BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25698532)

  • 1. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
    Miyake H; Harada K; Miyazaki A; Fujisawa M
    Med Oncol; 2015 Mar; 32(3):78. PubMed ID: 25698532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
    Buti S; Donini M; Bersanelli M; Gattara A; Leonardi F; Passalacqua R
    Drugs R D; 2017 Dec; 17(4):585-596. PubMed ID: 28895069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
    Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
    Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
    Makino K; Yoda K; Tomoishi J; Kume H
    BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
    Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
    Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
    Ezz El Din M
    Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
    Bracarda S; Negrier S; Casper J; Porta C; Schmidinger M; Larkin J; Gross Goupil M; Escudier B
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):227-233. PubMed ID: 28044472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
    J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
    Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
    Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
    Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
    J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
    Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
    Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
    Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
    Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
    Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
    Chin J Cancer; 2017 Aug; 36(1):64. PubMed ID: 28789709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
    Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
    Cella D; Davis MP; Négrier S; Figlin RA; Michaelson MD; Bushmakin AG; Cappelleri JC; Sandin R; Korytowsky B; Charbonneau C; Matczak E; Motzer RJ
    Cancer; 2014 Jun; 120(12):1871-80. PubMed ID: 24634003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
    Miyake H; Miyazaki A; Harada K; Fujisawa M
    Med Oncol; 2014 Jun; 31(6):978. PubMed ID: 24793747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
    Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L
    Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.